基于经导管动脉化疗栓塞联合治疗肝癌伴门静脉癌栓的进展

doi:10.3877/cma.j.issn.2095-5782.2024.01.011

肝细胞癌是最常见的恶性肿瘤之一，在确诊时就属于中晚期的阶段，一半以上患者伴有门静脉癌栓，在不进行相关干预治疗的情况下，中位生存期约为2.7个月。对于该类患者治疗方式的选择，我国还未有一致的共识，传统的治疗方式，如手术切除、肝移植、放射及靶向治疗等，效果仍不理想；伴随介入治疗的发展，以经导管动脉化疗栓塞（transcatheter arterial chemoembolization，TACE）为基础的联合治疗方案效果显著。本文将系统概述肝癌合并门脉癌栓的临床诊断、病理分型及以TACE为基础联合其他治疗方式的研究进展，为以后的临床工作提供参考。

关键词: 肝细胞癌, 门静脉癌栓, 经导管动脉化疗栓塞介入治疗

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Patients usually are diagnosed in the middle/advanced stage of HCC and more than half of the patients are accompanied by portal vein tumor thrombosis (PVTT). Without relevant intervention and treatment, the median survival period is about 2.7 months. There is no consensus in China on the choice of treatment methods for these patients. Traditional treatment methods, such as surgical treatment, liver transplantation, radiation therapy and targeted therapy still have unsatisfactory results. With the development of interventional treatment, the combined treatment based on transcatheter arterial chemoembolization (TACE) has shown significant efficacy. In this paper, the clinical diagnosis and pathological classification of hepatocellular carcinoma with portal vein tumor thrombosis and the research progress of TACE based combined with other therapy methods are summarized systematically, so as to provide reference for future clinical work.

Key words: Hepatocellular carcinoma, Portal vein cancer thrombosis, Transcatheter arterial chemoembolization intervention treatment

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249.
[2]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2022年版)[J].肝癌电子杂志, 2022, 9(1): 1-22.
[3]	王木子, 刘宏. 肝细胞癌合并门静脉癌栓诊疗进展[J]. 临床与病理杂志, 2023, 43(4): 827-835.
[4]	李玮, 王雯, 齐梦剑, 等. 肝癌合并门静脉癌栓局部治疗进展[J]. 中国实用外科杂志, 2023, 43(5): 591-596.
[5]	龚高全, 王小林, 王建华, 等. 肝癌门静脉支架植入术对门静脉压力的影响[J]. 介入放射学杂志, 2007, 16(3): 159-161.
[6]	程树群, 蔡建强, 陈敏山, 等. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]. 临床肝胆病杂志, 2019, 35(4): 737-743.
[7]	李红学, 刘连凤, 李航, 等. 超声技术在门静脉癌栓诊治中的研究进展[J]. 广西医科大学学报, 2020, 37(11): 2088-2091.
[8]	Chen J, Zhu J, Zhang C, et al. Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis[J]. Eur Radiol, 2020, 30(5): 2871-2880.
[9]	Seok JB, Min JL, Hee JY, et al. How to best detect portal vein tumor thrombosis in patients with hepatocellular carcinoma meeting the milan criteria: gadoxetic acid-enhanced MRI versus contrast-enhanced CT[J]. Liver Cancer, 2020, 9(3): 293-307.
[10]	李宏, 徐小虎, 彭进, 等. CT门静脉造影三维重建诊断门静脉癌栓的价值[J]. 中国CT和MRI杂志, 2022, 20(12): 101-102.
[11]	Li Y, Zhang Y, Fang Q, et al. Radiomics analysis of [¹⁸F] FDG PET/CT for microvascular invasion and prognosis prediction in very-early and early-stage hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2021, 48(11): 2599-2614.
[12]	Deng ZJ, Li L, Teng YX, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy[J]. J Clin Transl Hepatol, 2022, 10(1): 147-158.
[13]	中国医师协会肝癌专业委员会会议. 中国肝癌合并门静脉癌栓诊治指南(2021年版)[J]. 中华医学杂志, 2022, 102(4): 243-254.
[14]	Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update[J]. Biosci Trends, 2022, 16(1): 20-30.
[15]	Arno DF, Erwin H, Stijn HV, et al. Clinical management of chronic hepatitis B: a concise overview[J]. United European Gastroenterol J, 2022, 10(1): 115-123.
[16]	Lin DX, Zhang QY, Li X, et al. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus[J]. Journal of Cancer Research and Clinical Oncology, 2011, 137(1): 139-149.
[17]	奉建祁, 王志明. 中晚期原发性肝癌治疗的新进展[J]. 中国普通外科杂志, 2021, 30(7): 847-857.
[18]	Liu S, Li H, Guo L, et al. Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion[J]. Oncologist, 2019, 24(4): 513-520.
[19]	Zhang H, Cao G, Ren W, et al. Vascular normalization therapy with targeted localized vessel bevacizumab infusion in hepatocellular carcinoma after transarterial chemoembolization failure[J]. Ann Palliat Med, 2021, 10(8): 9149-9156.
[20]	Yuan J, Yin X, Tang B, et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study[J]. Biomed Res Int, 2019, 2019: 2141859.
[21]	Zhang X, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(17): 29416-29427.
[22]	林晓纯, 萧聪勤, 林坤鹏. 阿帕替尼联合肝动脉化疗栓塞术治疗肝癌合并门静脉癌栓的Meta分析[J]. 广州医科大学学报, 2022, 50(4): 34-41.
[23]	韩瑞瑞, 张锦, 马立翠, 等.原发性肝癌合并门静脉癌栓免疫治疗进展[J]. 肝脏, 2021, 26(2): 213-216.
[24]	张菊花, 陈珑, 刘宇杰, 等.原发性肝癌伴门脉癌栓患者行局部治疗联合PD-1治疗的不良反应观察护理[J]. 循证医学, 2020, 20(6): 351-356.
[25]	曹俊宁, 张雯雯, 赵海涛, 等.基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J].肝癌电子杂志, 2021, 8(2): 6-15.
[26]	Zou X, Xu Q, You R, et al. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features[J]. Cancer Medicine, 2023, 12(10): 11315-11333.
[27]	王亚运, 胡欢, 王世垚, 等. 三维适形放疗联合TACE治疗肝癌伴门静脉癌栓的有效性与安全性的Meta分析[J]. 西北国防医学杂志, 2018, 39(11): 704-710.
[28]	彭辉, 肖仁斌, 王江涛, 等. 经导管植入¹²⁵I放射性粒子治疗肝癌伴门静脉癌栓的效果[J]. 中国当代医药, 2019, 26(26): 82-84.
[29]	Han DH, Joo DJ, Kim MS, et al. Living donor liver transplantation for advanced hepatocellular carcinoma with portal vein tumor thrombosis after concurrent chemoradiation therapy[J]. Yonsei Med J, 2016, 57(5): 1276-1281.
[30]	梁军, 葛乃健, 过欣来, 等. 经皮门脉射频消融导管消融联合肝动脉化疗栓塞治疗肝癌伴Ⅲ型门静脉癌栓的临床疗效[J].肝胆外科杂志, 2020, 28(5): 345-348.
[31]	陆正华, 沈锋, 袁国新, 等. 肝癌门静脉癌栓的经皮激光消融治疗[J]. 中华外科杂志, 2004, 42(9): 57-60.
[32]	谌浩, 刘曦, 罗小平, 等. 经导管动脉化疗栓塞术联合高强度聚焦超声在原发性巨块型肝癌合并门脉癌栓治疗中的疗效评估[J]. 重庆医科大学学报, 2021, 46(1): 101-106.
[33]	韦伟, 关利君.TACE联合微波消融与联合¹²⁵I放射性粒子植入治疗不可切除肝癌合并门静脉癌栓疗效比较[J]. 介入放射学杂志, 2022, 31(9): 889-893.
[34]	Sun B, Zhang W, Chen L, et al. The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus[J]. Abdom Radiol (NY), 2022, 47(2): 858-868.
[35]	Pan Y, Wang R, Hu D, et al. Comparative safety and eflicacy of moleculer tageted druss. immune checkpoint in hibitors, hepstic atteral infusion chemotherapy and their combinations in adwaneed hepitocellular carcinoma, findings from advances in landmark trials[J]. Front Biosci ( Landmark Ed), 2021, 26(10): 873-881.
[36]	Long GB, Xiao CW, Zhao XY, et al. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis[J]. Medicine (Baltimore), 2020, 99(26): e20745.
[37]	柯映平, 叶绍光, 卢舜彬. 肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗对肝细胞癌伴门静脉癌栓患者的近期疗效[J]. 中国医药科学, 2022, 12(16): 156-159.
[38]	Yamakado K, Tanaka N, Nakatsuka A, et al. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein[J]. J Hepatol, 1999, 30(4): 660-668.
[39]	李红彬, 焦德超, 马波, 等. 门静脉支架同步¹²⁵I粒子条植入序贯经导管动脉化疗栓塞术治疗肝癌伴门静脉癌栓[J]. 中国医学影像技术, 2021, 37(3): 406-410.
[40]	周腾超, 田壮博, 龙林. 双导向技术引导下¹²⁵I粒子条联合门静脉支架植入术序贯经导管动脉化疗栓塞术治疗原发性肝细胞癌合并门静脉癌栓的有效性及安全性[J]. 肝癌电子杂志, 2022, 9(4): 52-58.
[41]	Zhang ZH, Hou SN, Yu JZ, et al. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: a propensity-score analysis[J]. Front Oncol, 2023, 12: 1086095.

[1]	丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 930-938.
[2]	李淼, 朱连华, 韩鹏, 姜波, 费翔. 高帧频超声造影评价肝细胞癌血管形态与风险因素的研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 911-915.
[3]	赵向阳, 刘双池, 张懿刚, 陶滔, 谈燚. 顺铂对肝细胞癌Hep3B细胞程序性死亡配体1表达及药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2024, 18(01): 51-55.
[4]	董杰, 杨松, 杨浩, 陈翔, 张万里. 乙酰辅酶A羧化酶2基因高甲基化与肝细胞癌临床病理因素和生存期的关系[J]. 中华普通外科学文献(电子版), 2023, 17(06): 433-437.
[5]	黄威, 刘启, 陈流华, 滕茶香, 区喆建, 刘韩笑, 陈健聪, 张昆松. 新定义的可预测肝癌预后的焦亡相关lncRNA模型[J]. 中华普通外科学文献(电子版), 2023, 17(05): 357-365.
[6]	王荣昌, 欧奇峰, 黄晋杰, 王彩琴, 汪谦, 黄晓卉. miR-145-5p在肝细胞癌中的表达及其临床意义[J]. 中华普通外科学文献(电子版), 2023, 17(03): 197-202.
[7]	郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[8]	马铭秀, 徐锋, 谢铠岭, 郭亚明, 卢潼辉, 戴朝六. 术前碱性磷酸酶-前白蛋白比值对肝细胞癌切除术预后的评估价值[J]. 中华普通外科学文献(电子版), 2023, 17(02): 99-103.
[9]	张琳成, 詹启帆, 赵禹迪, 邵初晓, 凌孙彬, 徐骁. 肝癌肝移植术后免疫抑制方案的网状荟萃分析[J]. 中华移植杂志(电子版), 2023, 17(06): 362-371.
[10]	曹亚娟, 黎兵华, 余德才. 转化治疗联合Laennec入路机器人右半肝切除治疗进展期肝癌[J]. 中华腔镜外科杂志(电子版), 2023, 16(02): 116-119.
[11]	万菲, 任勇军. 原发性肝细胞癌肿瘤标志物研究进展[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 77-81.
[12]	吴凤芸, 滕鑫, 刘连娟. 高帧频超声造影与增强磁共振对不同直径原发性高分化肝细胞癌的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 404-408.
[13]	胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[14]	刘中百, 任勇军. 肝细胞癌的介入治疗现状及进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 111-115.
[15]	梁伟, 王晓彬, 洪笑阳, 蔡明岳, 梁礼聪, 陈烨, 黄培凯, 刘铭宇, 林立腾, 朱康顺. 原位肝癌小鼠微波消融术后复发模型的构建[J]. 中华介入放射学电子杂志, 2023, 11(02): 133-139.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Progress in the treatment of liver cancer with portal vein thrombosis based on TACE

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Progress in the treatment of liver cancer with portal vein thrombosis based on TACE